Dr. Alexandria Phan on a CLARINET Study Subgroup Analysis
The CLARINET study led to the approval of lanreotide (Somatuline Depot) for the treatment of patients with advanced unresectable, metastatic gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs.)
Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses a subgroup analysis of the phase III CLARINET study.
gastrointestinal and pancreatic neuroendocrine tumors
(
The CLARINET study led to the approval of lanreotide (Somatuline Depot) for the treatment of patients with advanced unresectable, metastatic GEP-NETs), in December 2013. In the study, treatment with the somatostatin analog lanreotide improved progression-free survival by 53% compared with placebo for patients with grade 1 or 2 GEP-NETs.
The subgroup analysis took a closer look at the risks, benefits, and outcomes for patients taking lanreotide for the treatment of pancreatic neuroendocrine tumors (pNETs). Phan says the results of the analysis showed that the benefits of taking lanreotide as a first-line treatment outweighed the risks, and that the drug improved progression-free survival.
<<<
